Compare GKOS & GBCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GKOS | GBCI |
|---|---|---|
| Founded | 1998 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | 2015 | N/A |
| Metric | GKOS | GBCI |
|---|---|---|
| Price | $113.41 | $47.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $127.71 | $53.60 |
| AVG Volume (30 Days) | 641.9K | ★ 861.5K |
| Earning Date | 02-19-2026 | 01-22-2026 |
| Dividend Yield | N/A | ★ 2.78% |
| EPS Growth | N/A | ★ 26.70 |
| EPS | N/A | ★ 2.05 |
| Revenue | $469,820,000.00 | ★ $900,148,000.00 |
| Revenue This Year | $31.15 | $13.47 |
| Revenue Next Year | $24.15 | $27.72 |
| P/E Ratio | ★ N/A | $23.15 |
| Revenue Growth | ★ 30.38 | 15.35 |
| 52 Week Low | $73.16 | $36.76 |
| 52 Week High | $163.71 | $52.81 |
| Indicator | GKOS | GBCI |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 66.20 |
| Support Level | $109.07 | $46.16 |
| Resistance Level | $115.00 | $48.15 |
| Average True Range (ATR) | 2.76 | 1.14 |
| MACD | -0.95 | 0.20 |
| Stochastic Oscillator | 44.01 | 87.62 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.